Neurocognitive Effects of Opiate Agonist Treatment

PHASE4CompletedINTERVENTIONAL
Enrollment

135

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions
Opioid-Related DisordersHIVHIV Infections
Interventions
DRUG

Buprenorphine

Study participants will be randomly assigned 1:1 to buprenorphine (experimental/intervention) or methadone (active comparator). We will stratify by HIV status to ensure an equal number of HIV-infected participants in each group.

DRUG

Methadone

Study participants will be randomly assigned 1:1 to buprenorphine (experimental/intervention) or methadone (active comparator). We will stratify by HIV status to ensure an equal number of HIV-infected participants in each group.

Trial Locations (2)

10458

Fordham University, The Bronx

10467

Albert Einstein College of Medicine of Yeshiva University, The Bronx

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

collaborator

Montefiore Medical Center

OTHER

collaborator

Fordham University

OTHER

lead

Albert Einstein College of Medicine

OTHER

NCT01733693 - Neurocognitive Effects of Opiate Agonist Treatment | Biotech Hunter | Biotech Hunter